Amy Bolmer
Medical Oncology · Saint Ignace, MINPI 1366494270
Payments from drug & device makers
Across 433 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$742
- AstraZeneca$676
- Astellas Pharma US Inc$673
- Johnson & Johnson$497
- Eisai Inc.$482
- Pfizer$412
- plus $6K from 54 others
What the payments were for
- Food & beverage$8,13987%
- Education$1,25513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,394 in reported general payments places this provider in the 40th percentile of 170 medical oncology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $205,970 |
| EliquisApixaban | 11 | $6,699 |
| Exemestane | 19 | $2,323 |
| Anastrozole | 86 | $1,871 |
| Hydroxyurea | 47 | $977 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $694 |
| Tamoxifen Citrate | 17 | $648 |
| Potassium Chloride | 20 | $533 |
| Letrozole | 20 | $532 |
| Prochlorperazine Maleate | 17 | $302 |
| Dexamethasone | 11 | $245 |
| Allopurinol | 20 | $235 |
| Ondansetron Hcl | 31 | $226 |
| Omeprazole | 26 | $211 |
| Spironolactone | 25 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $412 | $212,66924 claims |
| Lilly USA, LLCOlanzapine | $388 | $3411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Saint Ignace
- Patricia Lo RussoDetroit$24.6M
- Manish SharmaGrand Rapids$19M
- Moshe TalpazAnn Arbor$13.7M
- Shirish GadgeelDetroit$11M
- Zachery ReichertAnn Arbor$10.6M
- Ammar SukariDetroit$8.4M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Emerson LimGrand Rapids$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.